Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis ; volume:16 ; number:1 ; day:30 ; month:9 ; year:2015 ; pages:1-16 ; date:12.2015
BMC musculoskeletal disorders ; 16, Heft 1 (30.9.2015), 1-16, 12.2015
- Urheber
-
Sun, Yubo
- Beteiligte Personen und Organisationen
-
Haines, Nikkole
Roberts, Andrea
Ruffolo, Michael
Mauerhan, David R.
Mihalko, Kim L.
Ingram, Jane
Cox, Michael
Hanley, Edward N.
SpringerLink (Online service)
- DOI
-
10.1186/s12891-015-0724-x
- URN
-
urn:nbn:de:1111-2016110516516
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sun, Yubo
- Haines, Nikkole
- Roberts, Andrea
- Ruffolo, Michael
- Mauerhan, David R.
- Mihalko, Kim L.
- Ingram, Jane
- Cox, Michael
- Hanley, Edward N.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Disease-Modifying Therapies in Multiple Sclerosis
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
Disease-modifying treatments in Alzheimer’s disease
Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020
MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy
The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Disease-Modifying Therapies in Multiple Sclerosis
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
Disease-modifying treatments in Alzheimer’s disease
Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020
MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy
The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Disease-Modifying Therapies in Multiple Sclerosis
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
Disease-modifying treatments in Alzheimer’s disease
Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020
MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy
The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Disease-modifying effects of ranibizumab for central retinal vein occlusion